A randomized clinical trial followed men for 3.8 years to see if testosterone replacement therapy (TRT) reduced mortality in men with type 2 diabetes mellitus (T2DM). It did, even though it had no effect on cardiovascular disease (CVD). rates. The abstract says:
"We studied 857 men with T2DM, screened for the BLAST RCT, over 3.8 years follow‐up. The men were stratified by testosterone levels; Group 1: total testosterone (TT) >12nmol/l and free testosterone (FT) >0.25nmol/l, Group 2: TT ≤12nmol/l or FT ≤0.25nmol/l and by TRT (Group 2 further stratified into those not on TRT (Group 2a) and on TRT (Group 2b). Group 2b was further stratified by whether TRT was discontinued (Group 2b1) or not (Group 2b2). The principal outcome, mortality, was studied using Cox regression."
"TRT was not associated with improvements in the CVD risk factors. The CVD risk factors (baseline and changes during follow‐up) were not associated with mortality. Men in Group 1 and Group 2b demonstrated lower mortality (reference: Group 2a) even with CVD risk factors included in regression models. Mortality was lower in the Group 2b1 (6.2%) and Group 2b2 men (0%) compared to Group 2a men (16.9%). The lower mortality associated with Group 1 and Group 2b was primarily in older (>64.6 years) and less overweight (≤93.8Kg) men."
"The benefits associated with normal testosterone levels and TRT (even after discontinuation) do not appear to be related to improvements in the CVD risk factors studied. In view of TRT having greater impact in men of lower weight, better outcomes may be achieved with concurrent TRT and weight reduction programmes."
"We studied 857 men with T2DM, screened for the BLAST RCT, over 3.8 years follow‐up. The men were stratified by testosterone levels; Group 1: total testosterone (TT) >12nmol/l and free testosterone (FT) >0.25nmol/l, Group 2: TT ≤12nmol/l or FT ≤0.25nmol/l and by TRT (Group 2 further stratified into those not on TRT (Group 2a) and on TRT (Group 2b). Group 2b was further stratified by whether TRT was discontinued (Group 2b1) or not (Group 2b2). The principal outcome, mortality, was studied using Cox regression."
"TRT was not associated with improvements in the CVD risk factors. The CVD risk factors (baseline and changes during follow‐up) were not associated with mortality. Men in Group 1 and Group 2b demonstrated lower mortality (reference: Group 2a) even with CVD risk factors included in regression models. Mortality was lower in the Group 2b1 (6.2%) and Group 2b2 men (0%) compared to Group 2a men (16.9%). The lower mortality associated with Group 1 and Group 2b was primarily in older (>64.6 years) and less overweight (≤93.8Kg) men."
"The benefits associated with normal testosterone levels and TRT (even after discontinuation) do not appear to be related to improvements in the CVD risk factors studied. In view of TRT having greater impact in men of lower weight, better outcomes may be achieved with concurrent TRT and weight reduction programmes."
